Oct. 29, 2013
/PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced the results from the US Phase IIa trial of TG-0054, a CXC chemokine receptor 4 (CXCR4) antagonist, in stem cell transplantation will be presented in an Oral Session at the 55th ASH Annual Meeting and Exposition (
December 7-10, 2013
New Orleans, LA
Title: Rapid Mobilization Of CD34+ Stem Cells With TG-0054, a Novel CXC Chemokine Receptor 4 (CXCR4) Antagonist Session Name: 711. Cell Collection and Processing II Session Date:
Tuesday, December 10, 2013
7:30 AM - 9:00 AM
Room: Ernest N. Morial Convention Center, Riverside Rooms - R02-R03
In addition to the presentation, the abstract will also be published online in the
November 15, 2013
supplemental volume of the journal, Blood.
TG-0054, also known as burixafor, is a novel, potent and selective chemokine receptor antagonist. TG-0054 rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. TG-0054 has already completed Phase 1 study in healthy volunteers in the US. In addition to stem cell transplantation, other potential indications include chemosensitization and ischemic diseases.
About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in
with a wholly-owned subsidiary in
, mainland China. In addition to TG-0054, TaiGen has two other NCEs in development: Nemonoxacin (oral formulation) has completed Phase 3 trials for community-acquired pneumonia and NDA submitted to regulatory authorities in mainland
; and TG-2349 is a pan-genotypic NS3/4A protease inhibitor currently in Phase 1/2a trials in the US.
For more information please contact:
Peter W. Tsao
, PhD, Vice President of Business DevelopmentTel: +886-2-8177-7072 ext 1705
, Vice President of OperationsTel. +886-2-8177-7072 ext 1704
SOURCE Taigen Biotechnology